Navigation Links
Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Date:10/5/2010

condary AML. The safety and efficacy of Neulasta administration in de novo AML patients aged < 55 years with cytogenetics t(15;17) have not been established.

Neulasta should be discontinued following preliminary signs of ARDS.  Spleen size should be carefully monitored and caution exercised when administering in patients with sickle cell disease.  Safety and efficacy of Neulasta for mobilisation of blood progenitor cells in patients or healthy donors has not been adequately evaluated.  

Other adverse events of special importance associated with Neulasta include bone pain, allergic-type reactions including anaphylaxis (pegfilgrastim should be permanently discontinued in patients who experience a serious allergic reaction) and very rare cases of splenic rupture including fatal cases.  Neulasta should be administered approximately 24 hours after administration of cytotoxic chemotherapy.

About AranespAranesp was approved by the FDA in 2001 for the treatment of anemia associated with CRF for patients on dialysis and patients not on dialysis. The European Commission granted marketing authorization for the same indication in 2001 and subsequently updated it for CRF patients with symptomatic anemia in 2008.

In 2002, the FDA approved Aranesp for the treatment of anemia caused by concomitantly administered chemotherapy in patients with nonmyeloid malignancies. The European Commission authorized the treatment of anemia caused by concomitantly administered chemotherapy in patients with non-haematological malignancies in 2002 and extended it to include non-myeloid malignancies in patients receiving chemotherapy in 2003.

Important U.S. Product Safety InformationAranesp is indicated for the treatment of anemia due to the effect of concomitantly administered chemotherapy based on studies that have shown a reduction in the need for red blood cell transfusions in patients with metastatic, non-myeloid malignancies
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Calif., July 31, 2014 STAAR Surgical Company ... and marketer of implantable lenses and delivery systems for ... ended July 4, 2014 of $20.0 million, a 10% ... of 2013. On a constant currency basis, revenues grew ... the second quarter of 2013.  The effect of foreign ...
(Date:7/31/2014)... 31, 2014 Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® Insulin Pump, today reported its financial results for ... comparing the second quarter of 2014 to the same period ... million from $5.5 million , t:slim Pump shipments grew ... In comparing six months ended June 30, 2014 to the ...
(Date:7/31/2014)... -- Cepheid (NASDAQ: CPHD ) today announced that its ... investors to participate via webcast. Wedbush ... Wednesday, August 13, 2014 at 9.10 a.m. Eastern ... New York, NY Thursday, September 4, 2014 at ... To access the live webcasts for these events, please visit ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6
(Date:7/31/2014)... GA (PRWEB) July 31, 2014 Developer ... camera on its Ponce City Market project in ... historic Sears, Roebuck & Company building into best-in-class office, ... completion, OxBlue reviewed Jamestown’s experience with their construction webcam ... , Jamestown wanted a construction camera ...
(Date:7/31/2014)... Lake Leelanau, MI (PRWEB) July 31, 2014 ... doors on Thursday, July 3, 2014 at 7788 East Horn ... Leelanau Peninsula Wine Trail , Aurora Cellars is the ... all trail activities including the popular wine tour events, making ... and Sunday, September 6-7, 2014. , Owners David and ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:7/31/2014)... 2014 Ce-Classes.com has announced that they ... healthcare professionals, a Systematic Review of Sexual Satisfaction ... in the International Journal of Clinical and Health Psychology. ... to a need to have accurate information about sexual ... treatment possible. The material provides a systematic review ...
(Date:7/31/2014)... In many states and counties across the country, ... life saving drugs. This requirement is for the safety of ... number of ambulances without proper security procedures. , In extreme ... even replaces the vital pain killers with saline. Later, the ... case in Baraboo, Wisconsin last November. According to court documents, ...
Breaking Medicine News(10 mins):Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2
... By Jenifer Goodwin HealthDay Reporter ... experimental drug reduced two signature characteristics of autism ... in laboratory mice, new research finds. The ... throughout the brain that,s involved with activating neurons, ...
... become known as "pink slime" actually seemed like a triumph of ... and, at one point, even got rave reviews in the news ... Chemical & Engineering News . C&EN is the weekly ... In the article, Carmen Drahl, C&EN associate editor, ...
... the stomachs of pigs could be a long-sought, abundant source ... to supplement baby formula and for use in personal hygiene ... viral infections. Their study appears in ACS, journal Biomacromolecules ... out that mucus, which coats the inside of the nose, ...
... France, 19 April 2012: The European Society of Cardiology ... Heart Journal: Acute Cardiovascular Care , the organisation,s official ... Care. "This new journal will be an ... professionals, offering useful information for daily clinical practice to ...
... HealthDay Reporter , TUESDAY, April 24 (HealthDay News) -- After ... least one state may finally be turning things around. ... 6 in eastern Massachusetts declined during the period between 2004 ... also found that the rates of obesity declined more for ...
... Together with child and adolescent psychiatrists, researchers from the University ... the studies which have been done so far on the ... The report shows that there are potential benefits in changing ... in the area is still lacking. The comprehensive report ...
Cached Medicine News:Health News:Experimental Drug Eases Autistic Behaviors in Mice 2Health News:Experimental Drug Eases Autistic Behaviors in Mice 3Health News:Experimental Drug Eases Autistic Behaviors in Mice 4Health News:Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC 2Health News:Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC 3Health News:Could the Childhood Obesity 'Epidemic' Be Ebbing? 2Health News:Could the Childhood Obesity 'Epidemic' Be Ebbing? 3Health News:Dietary changes help some children with ADHD 2
... addition to Laserscopes family of multi-application laser ... from, 1064nm Nd:YAG and 532nm KTP, the ... aesthetic laser market by pushing the envelope ... the safety and reliability record of a ...
... a new, portable, light weight, high power ... cosmetic and plastic surgery, general surgery, ENT ... resurfacing, it is the smallest, yet among ... market. It provides an ideal treatment for ...
... Series, including the Ceralas D and ... soft-tissue applications in medical, dental, and ... water and hemoglobin, the 980 nm ... and provide a bloodless field for ...
... Venus-i™ Laser System is a new, portable, ... with applications in dermatology, cosmetic and plastic ... ideal laser for skin resurfacing, it is ... Erbium:YAG lasers on the market. It provides ...
Medicine Products: